US/UK/Canada

Share

Contacts

  • Mikael Wegmüller

    VP, Communications and Sustainability


    +358 40 776 2314
  • Marina Nordén

    External Communications Manager


    +46 761 099 163
    • Pick a time period -
    Tags ( Active)

    Oriola Corporation to publish its Interim Report for January-March 2024 on 25 April 2024

    Oriola Corporation  Investor news  11 April 2024 at 9:00 a.m. EEST  Oriola Corporation to publish its Interim Report for January-March 2024 on 25 April 2024   Oriola Corporation will publish its Interim Report for January-March 2024 on Thursday 25 April 2024 at around 8:30 a.m. EEST. The Interim Report will be available on Oriola’s website after the publication. Welcome to join our results presentation CEO Katarina Gabrielson and CFO Timo Leinonen will present the Q1 results at a webcast meeting on the same day starting at 10.00 a.m. EEST. The link to the webcast will be

    Resolutions of the Annual General Meeting of Oriola Corporation and the decisions of the constitutive meeting of the Board of Directors

    Oriola Corporation's Stock Exchange Release 19 March 2024 at 7.00 p.m. Resolutions of the Annual General Meeting of Oriola Corporation and the decisions of the constitutive meeting of the Board of Directors A. Oriola Corporation's Annual General Meeting held on 19 March 2024 passed the following resolutions: 1. Adoption of the financial statements and discharge from liability The AGM adopted the financial statements and discharged the members of the Board of Directors and the President and CEOs from liability for the financial year ending 31 December 2023. 2. Payment of

    Oriola Corporation’s disposal of own shares based on the share-based incentive plan

    Oriola Corporation Stock Exchange Release 15 March 2024 at 2.30 p.m. EET Oriola Corporation’s disposal of own shares based on the share-based incentive plan A total of 11,714 Oriola Corporation’s class B treasury shares are conveyed without consideration to the key employees participating in the PSP Bridge Plan 2022-2023 in accordance with the terms and conditions of the plan. The resolution on the directed share issue is based on the authorisation granted to the Board of Directors by the Annual General Meeting of Shareholders held on 21 March 2023. Following this directed share

    Oriola provides restated financial information for the new reporting segments

    Oriola Corporation  Stock Exchange Release  15 March 2024 at 9.00 a.m. EET Oriola provides restated financial information for the new reporting segments Oriola’s segment reporting changed from one to two reporting segments as of 1 January 2024 to reflect the strategy published on 31 October 2023 and to improve transparency. Oriola has restated the financial information for 2022 and 2023 according to the new reporting segments. From 1 January 2024 onwards, Oriola’s reporting segments are: · Distribution segment consisting of pharmaceutical logistics and dose dispensing services.

    Oriola Corporation's Annual Report 2023 published

    Oriola Corporation  Stock Exchange Release  27 February 2024 at 1:00 p.m. EET Oriola Corporation's Annual Report 2023 published Oriola Corporation has today published its Annual Report for the year 2023. Oriola’s Annual Report consists of the following sections: Business review, Sustainability report, Corporate governance statement, Remuneration report, Report of the Board of Directors and Financial statements. Sustainability data has been prepared in accordance with the GRI Universal Standards 2021. The environmental data has been assured by a third party (limited assurance).

    Notice to Oriola Corporation’s Annual General Meeting 2024

    Oriola Corporation Stock Exchange Release 16 February 2024 at 12:00 p.m. EET Notice to Oriola Corporation’s Annual General Meeting 2024 Notice is given to the shareholders of Oriola Corporation (“Oriola” or the “Company”) to the Annual General Meeting to be held on Tuesday 19 March 2024 starting at 3:00 p.m. (EET) at Hanasaari at the address Hanasaarenranta 5, FI-02100 Espoo, Finland, the Celsius Auditorium, entrance 1st floor. The reception of persons who have registered for the meeting and distribution of the voting tickets at the meeting venue will commence at 2:00 p.m. (EET).

    Oriola Corporation’s Financial Statements Release 1 January-31 December 2023

    Oriola Corporation Stock Exchange Release 16 February 2023 at 8.30 a.m. EET Oriola Corporation’s Financial Statements Release 1 January-31 December 2023 Strong growth in profitability excluding Swedish dose dispensing business October-December 2023 highlights · Invoicing increased by 6.2 % to EUR 963.4 (906.9). On a constant currency basis, invoicing increased by 9.7% and was EUR 994.7 million. · Net sales increased by 1.7% to EUR 386.6 (380.0) million. On a constant currency basis, net sales increased by 4.8% and were EUR 398.2 million. · Adjusted EBIT was EUR 5.4 (2.9)

    Oriola Corporation to publish its Financial Statements Release 2023 on 16 February 2024

    Oriola Corporation  Investor news  2 February 2024 at 9:00 a.m. EET  Oriola Corporation to publish its Financial Statements Release 2023 on 16 February 2024   Oriola Corporation will publish its Financial Statements Release 2023 on Friday 16 February 2024 at around 8:30 a.m. EET. The Financial Statements Release will be available on Oriola’s website after the publication.  Welcome to join our results presentation  CEO Katarina Gabrielson and CFO Timo Leinonen will present the full-year results at a webcast meeting on the same day starting at 10.00 a.m. EET. The link to the

    The Swedish Competition Authority moves its investigation of Oriola’s sale of Svensk dos AB to Apotekstjänst Sverige AB into phase II

    Oriola Corporation  Stock Exchange Release  31 January 2024 at 9:00 a.m. EET The Swedish Competition Authority moves its investigation of Oriola’s sale of Svensk dos AB to Apotekstjänst Sverige AB into phase II The Swedish Competition Authority (Konkurrensverket) moves its investigation of Oriola’s sale of Svensk dos AB to Apotekstjänst Sverige AB into phase II. Oriola announced on 13 October 2023 the sale of all shares in Svensk dos AB to Apotekstjänst Sverige AB. In addition, Oriola communicated that it had not identified a recovery of the business within the foreseeable future,

    Proposals of the Shareholders’ Nomination Board of Oriola Corporation concerning the Board of Directors to be elected by the 2024 Annual General Meeting

    Oriola Corporation Stock Exchange Release 24 January 2024 at 10:00 a.m. EET Proposals of the Shareholders’ Nomination Board of Oriola Corporation concerning the Board of Directors to be elected by the 2024 Annual General Meeting Oriola’s Shareholders’ Nomination Board has presented its proposal to the 2024 Annual General Meeting concerning the composition of the Board of Directors as follows: · The number of members of the Board of Directors would be seven · The present members of the Board of Directors Nina Mähönen, Yrjö Närhinen, Ellinor Persdotter Nilsson, Harri Pärssinen

    Oriola to invest in ERP and warehouse management as part of the recently launched strategy to enhance efficiency and operational excellence

    Oriola Corporation  Investor news  10 January 2024 at 11:00 a.m. EET Oriola to invest in ERP and warehouse management as part of the recently launched strategy to enhance efficiency and operational excellence Oriola will be investing in its infrastructure as part of its refined strategy, published in October 2023, with the aim to enhance efficiency and operational excellence. Enhanced efficiency is one of the three goals set by Oriola to drive the strategy forward. The investment comprises the renewal of Oriola’s ERP (enterprise resource planning) and warehouse management system

    Study reveals opioid treatment barriers in high-risk users in Finland

    A recent study shows that many high-risk opioid users do not enter treatment even though the most common reason for opioid use is self-medication for withdrawal symptoms[1]. The study uncovered several barriers hindering access to treatment, urging immediate action to address this critical trend in Finland. Over the past decade, Finland has witnessed a significant rise in opioid misuse, doubling the number of high-risk opioid users. In recent years, opioids have been involved in approximately 70% of fatal overdoses in Finland, especially among individuals under 25 years of age[2]. This

    Oriola changes its segment reporting and publishes preliminary figures

    Oriola Corporation Stock Exchange Release  31 October 2023 at 8:40 a.m. EET Oriola changes its segment reporting and publishes preliminary figures Oriola is updating its segment reporting to reflect the new strategy, announced on 31 October 2023, and to improve transparency. Oriola’s two reporting segments as of 1 January 2024 will be: · Distribution segment consisting of pharmaceutical logistics and dose dispensing services. · Wholesale segment consisting of wholesale of traded goods and over-the-counter (OTC) products, parallel import and special licensed medicines, as well

    Oriola announces strategy, financial targets and sustainability agenda: The leading specialist in wholesale of pharmaceuticals and health products

    Oriola Corporation  Stock Exchange Release  31 October 2023 at 8:35 a.m. EET Oriola announces strategy, financial targets and sustainability agenda: The leading specialist in wholesale of pharmaceuticals and health products Oriola’s Board of Directors have decided on Oriola’s refined strategy, new long-term financial targets and sustainability agenda. The period for the strategy and sustainability agenda is 2024–2026. “For the past two years, our focus has been on Oriola’s long-term transformation. This journey has meant reconnecting with our roots, as our strength is in the

    Oriola Corporation’s Interim Report January-September 2023

    Oriola Corporation Stock Exchange Release 31 October 2023 at 8.30 a.m. EET Oriola Corporation’s Interim Report January-September 2023 Solid sales growth in Distribution business, strong financial position July–September 2023 highlights · Invoicing was EUR 861.7 (870.6) million and slightly below the previous year’s level. On a constant currency basis, invoicing increased by 5.7% and was EUR 920.6 million. · Net sales decreased by 5.7% to EUR 352.6 (373.9) million. On a constant currency basis, net sales increased by 0.7% and were EUR 376.5 million. · Adjusted EBIT was

    Oriola Corporation to publish its Interim Report for January–September 2023 on 31 October 2023

    Oriola Corporation  Investor news  17 October 2023 at 8:30 a.m. EEST Oriola Corporation to publish its Interim Report for January–September 2023 on 31 October 2023 Oriola Corporation will publish its Interim Report for January–September 2023 on Tuesday 31 October 2023 at around 8:30 a.m. EEST. The Interim Report will be available on Oriola’s website after the publication. Welcome to join our results presentation CEO Katarina Gabrielson and CFO Timo Leinonen will present the Interim Report at a webcast meeting on the same day starting at 10.00 a.m. EEST. The link to the webcast

    Inside information: Oriola to sell Svensk dos AB to Apotekstjänst Sverige AB – new outlook for 2023 issued

    Oriola Corporation  Stock Exchange Release  13 October at 8:50 p.m. EEST Inside information: Oriola to sell Svensk dos AB to Apotekstjänst Sverige AB – new outlook for 2023 issued Oriola Corporation has today signed an agreement to sell all shares in Svensk dos AB to Apotekstjänst Sverige AB, and is thereby exiting the dose dispensing business in Sweden. Svensk dos AB has lost market share during the past 12 months due to the loss of public tender contracts, as has been communicated earlier in Oriola’s financial reports. At the end of Q2 2023 Svensk dos served approximately 11,000

    Composition of Oriola Corporation’s Shareholders’ Nomination Board

    Oriola Corporation Stock Exchange Release 27 September 2023 at 3.00 p.m. Composition of Oriola Corporation’s Shareholders’ Nomination Board The largest shareholders of Oriola Corporation have in accordance with the rules of procedure of the Shareholders’ Nomination Board appointed the following persons members of the Nomination Board: Annika EkmanPeter ImmonenTimo MaasiltaPekka PajamoJukka Ylppö Pekka Pajamo was elected chairman of the Nomination Board. Heikki Westerlund, Chairman of the Board of Directors of Oriola, will serve as an expert member of the Nomination

    Orion and Oriola to continue partnership in Finland

    Orion and Oriola are renewing their distribution agreement in Finland. According to the agreement, Oriola will continue to provide warehousing and distribution services for Orion’s human and veterinary pharmaceuticals in Finland. The new agreement was signed on 29 June 2023, and is effective from 1 July 2024. The close cooperation of the two Finnish companies will continue to secure quality and timely distribution of pharmaceuticals to the Finnish healthcare sector. “I’m very pleased with the continuation of our partnership. Oriola and Orion have a long history of working together. As

    Publication schedule for Oriola Corporation's financial reporting in 2024

    Oriola Corporation Stock Exchange Release 21 July 2023 at 8:45 a.m. EEST Publication schedule for Oriola Corporation's financial reporting in 2024 Oriola Corporation will publish its Financial Statements Release for 1 January-31 December 2023 on Friday 16 February 2024. The publication dates of the financial reports in 2024 are as follows: · Interim Report 1-3/2024 on Thursday 25 April 2024 · Half-Year Report 1-6/2024 Thursday 18 July 2024 · Interim Report 1-9/2024 on Wednesday 30 October 2024 Oriola Corporation's Annual General Meeting is planned to be held on

    Oriola Corporation’s Half-Year Report January-June 2023

    Oriola Corporation Stock Exchange Release 21 July 2023 at 8.30 a.m. EEST Oriola Corporation’s Half-Year Report January-June 2023 Solid performance in Distribution business, profitability burdened by Dose Sweden April–June 2023 highlights · Invoicing was EUR 904.3 (903.9) million and slightly above the previous year’s level. On a constant currency basis, invoicing increased by 6.0% and was EUR 958.2 million. · Net sales decreased by 2.8% to EUR 383.6 (394.6) million. On a constant currency basis, net sales increased by 3.0% and were EUR 406.5 million. · Adjusted EBIT was

    Oriola Corporation to publish its Half-Year Report for January–June 2023 on 21 July 2023

    Oriola Corporation  Investor news  6 July 2023 at 8:30 a.m. EEST Oriola Corporation to publish its Half-Year Report for January–June 2023 on 21 July 2023 Oriola Corporation will publish its Half-Year Report for January–June 2023 on Friday 21 July 2023 at around 8:30 a.m. EEST. The Half-Year Report will be available on Oriola’s website after the publication. Welcome to join our results presentation CEO Katarina Gabrielson and CFO Timo Leinonen will present the Half-Year Report at a webcast meeting on the same day starting at 10.00 a.m. EEST. The link to the webcast will be

    Oriola Corporation’s disposal of own shares based on the share-based incentive plan

    Oriola Corporation Stock Exchange Release 1 June 2023 at 9:00 a.m. EEST Oriola Corporation’s disposal of own shares based on the share-based incentive plan A total of 22,138 Oriola Corporation’s class B treasury shares are conveyed without consideration to the key employees participating in the Share Savings Plan OKShares 2020 in accordance with the terms and conditions of the plan. The resolution on the directed share issue is based on the authorisation granted to the Board of Directors by the Annual General Meeting of Shareholders held on 15 March 2022. Following this directed

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media